Rhythm Pharmaceuticals, Inc. is an American pharmaceutical company specializing in developing and selling therapies for rare diseases. They focus on peptide therapeutics for treating gastrointestinal conditions and genetic metabolic disorders. Their leading product candidate is setmelanotide (RM 493), designed to address rare genetic obesity disorders. With an ESG score of 25.7, Rhythm Pharmaceuticals is considered a medium-risk investment. The company generates revenue mainly from the United States and Germany.